Protalix BioTherapeutics For Profit
Protalix is dedicated to bringing to market recombinant therapeutic proteins with clinically improved profiles, produced with its ProCellEx® plant cell-based expression system
Investors
Founded Date:
1994-01-01
Total Funding:
$10.8M
Employee Number:
501-1000
Funding Status:
IPO
Technology:
Drug development
Last Funding Type:
Seed
Investors Number:
1
Industry:
PharmTech
Headquarters:
Carmiel, HaZafon, Israel
Estimated Revenue:
$10M to $50M